Comment on "clinical trials update from the European Society of Cardiology meeting 2005: CIBIS-III, by JGF Cleland and others" [4]

European Journal of Heart Failure

Volumn 8, Issue 2, 2006, Pages 219-220

  Willenheimer, Ronnie ^a   Krum, Henry ^b   Van Veldhuisen, Dirk J ^c   Funck Brentano, Christian ^d   Erdmann, Erland ^e   Meyer, Wilfried R ^f  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITY OF COLOGNE   (Germany)

^f MERCK KGAA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE EXACERBATION; DRUG MEGADOSE; HEART FAILURE; HOSPITALIZATION; HUMAN; LETTER; MONOTHERAPY; MORBIDITY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SURVIVAL; TITRIMETRY;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BISOPROLOL; ENALAPRIL; HEART FAILURE; HOSPITALIZATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 32544461831     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2006.01.006     Document Type: Letter

References (8)

1. J.G. Cleland, A.P. Coletta, M. Lammiman, K.K. Witte, H. Loh, and M. Nasir Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE Eur J Heart Fail 7 2005 1070 1075
2. R. Willenheimer, D.J. van Veldhuisen, B. Silke, E. Erdmann, F. Follath, H. Krum CIBIS III Investigators Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III Circulation 112 2005 2426 2435
3. R. Willenheimer, E. Erdmann, F. Follath, H. Krum, P. Ponikowski, B. Silke CIBIS-III investigators Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III Eur J Heart Fail 6 2004 493 500
4. K. Swedberg, J. Cleland, H. Dargie, H. Drexler, F. Follath, and M. Komajda Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005) Eur Heart J 26 2005 1115 1140
5. J.G. Cleland, A. Cohen-Solal, J.C. Aguilar, R. Dietz, J. Eastaugh, F. Follath IMPROVEMENT of Heart Failure Programme Committees and Investigators Improvement programme in evaluation and management; Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey Lancet 360 2002 1631 1639
6. M. Davies, F. Hobbs, R. Davis, J. Kenkre, A.K. Roalfe, and R. Hare Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study Lancet 358 2001 439 444
7. M. Komajda, P. Lapuerta, N. Hermans, J.R. Gonzalez-Juanatey, D.J. van Veldhuisen, and L. Tavazzi Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey Eur Heart J 26 2005 1653 1659
8. W.J. Remme, G. Riegger, P. Hildebrandt, M. Komajda, W. Jaarsma, and M. Bobbio The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN) Cardiovasc Drugs Ther 18 2004 57 66